{
    "clinical_study": {
        "@rank": "144421", 
        "arm_group": {
            "arm_group_label": "AN2728 Topical Ointment, 2%", 
            "arm_group_type": "Experimental", 
            "description": "AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the safety, tolerability, and systemic exposure\n      of AN2728 Topical Ointment, 2%, in subjects with atopic dermatitis."
        }, 
        "brief_title": "Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "Dermatitis, Atopic", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female 12 to 17 years of age, inclusive\n\n          -  Clinical diagnosis of atopic dermatitis (according to the criteria of Hanifin and\n             Rajka)\n\n          -  AD in treatable areas (excludes the scalp and venous access areas) involving\n\n             \u226510% and \u226435% of the total body surface area(BSA)\n\n          -  Investigator's Static Global Assessment (ISGA) score of 2 or 3\n\n          -  Normal or not clinically significant screening laboratory results\n\n          -  Have adequate venous access to permit repeated PK sampling on Days 1 - 9 through\n             uninfected skin that has not been treated with study drug; each untreated venous\n             access area should provide a margin of at least 5 cm radius around the venipuncture\n             site\n\n          -  Willing and able to comply with study instructions and commit to attending all visits\n\n          -  Females must use a highly effective method of birth control.\n\n          -  Parent/guardian has the ability to understand, agree to and sign the study Informed\n             Consent Form (ICF) prior to initiation of any protocol-related procedures; subject\n             has the ability to give assent\n\n        Exclusion Criteria:\n\n          -  Significant confounding conditions as assessed by study doctor\n\n          -  Unstable or actively infected AD\n\n          -  Active or potentially recurrent dermatologic condition other than atopic dermatitis\n             that may confound evaluation\n\n          -  History or evidence of allergies requiring acute or chronic treatment (except\n             seasonal allergic rhinitis)\n\n          -  Concurrent or recent use of certain topical or systemic medications or phototherapy\n             without a sufficient washout period\n\n          -  Treatment for any type of cancer (except squamous cell carcinoma, basal cell\n             carcinoma, or carcinoma in situ of the skin, curatively treated with cryosurgery or\n             surgical excision only) within the last 5 years\n\n          -  Current pregnancy or lactation, or intent to become pregnant during the study\n\n          -  Known sensitivity to any of the components of the study drug\n\n          -  Participated in any other trial of an investigational drug or device within 30 days\n             or participation in a research study concurrent with this study\n\n          -  Participated in a previous AN2728 clinical study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "23", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01652885", 
            "org_study_id": "AN2728-AD-203"
        }, 
        "intervention": {
            "arm_group_label": "AN2728 Topical Ointment, 2%", 
            "description": "AN2728 Topical Ointment, 2%", 
            "intervention_name": "AN2728 Topical Ointment, 2%", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "atopic dermatitis", 
        "lastchanged_date": "February 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fremont", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94538"
                    }, 
                    "name": "Anacor Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92123"
                    }, 
                    "name": "Anacor Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46256"
                    }, 
                    "name": "Anacor Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "High Point", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27262"
                    }, 
                    "name": "Anacor Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winston-Salem", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27104"
                    }, 
                    "name": "Anacor Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Anacor Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of AN2728 Ointment in Adolescents With Atopic Dermatitis", 
        "overall_official": {
            "affiliation": "Anacor Pharmaceuticals, Inc.", 
            "last_name": "Lee Zane, MD, MS, MAS", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Descriptive summarization of safety and tolerability (frequency and severity of systemic and local AEs)", 
            "measure": "Assessment of safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "up to 28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01652885"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Cmax, Area Under Curve, Tmax, t1/2", 
                "measure": "Profile of pharmacokinetics on Days 2,4,6,9 at timepoints 0,1,2,4,6,8 hrs post-dose (only timepoint 0 on Day 9)", 
                "safety_issue": "No", 
                "time_frame": "Dosing days 2, 4, 6, 9"
            }, 
            {
                "description": "Achievement of treatment success (defined as a score of Clear or Almost Clear with a 2-grade improvement from Baseline) will be based on the ISGA, a 5-point scale from 0 (clear) to 4 (severe)", 
                "measure": "Achievement of treatment success", 
                "safety_issue": "No", 
                "time_frame": "up to 28 days"
            }, 
            {
                "description": "Improvement from Baseline in the signs and symptoms of AD, including erythema, excoriation, exudation, lichenification, and pruritus, will be based on a 4-point scale from 0 (none) to 3 (severe)", 
                "measure": "Improvement in the signs and symptoms of atopic dermatitis", 
                "safety_issue": "No", 
                "time_frame": "up to 28 days"
            }
        ], 
        "source": "Anacor Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Anacor Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}